LYK5 (STRADA) Human shRNA Plasmid Kit (Locus ID 92335)

CAT#: TL320748

STRADA - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

Specifications

Product Data

• Locus ID: 92335
• Synonyms: LYK5; NY-BR-96; PMSE; Stlk; STRAD; STRAD alpha
• Vector: pGFP-C-shLenti
• Format: Lentiviral plasmids
• Kit Components: STRADA - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 92335). 5µg purified plasmid DNA per construct
  Non-effective 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
• RefSeq: NM_001003786, NM_001003787, NM_001003788, NM_001165969, NM_001165970, NM_153335, BC043641, NM_001363786, NM_001363787, NM_001363789, NM_001363790, NM_001363791, NM_001363788, NR_156741
• Summary: The protein encoded by this gene contains a STE20-like kinase domain, but lacks several residues that are critical for catalytic activity, so it is termed a 'pseudokinase'. The protein forms a heterotrimeric complex with serine/threonine kinase 11 (STK11, also known as LKB1) and the scaffolding protein calcium binding protein 39 (CAB39, also known as MO25). The protein activates STK11 leading to the phosphorylation of both proteins and excluding STK11 from the nucleus. The protein is necessary for STK11-induced G1 cell cycle arrest. A mutation in this gene has been shown to result in polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome. Multiple transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their full-length nature is not known. [provided by RefSeq, Sep 2009]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).